Cypress Bioscience (CYPB) Says Phase IIa Trials Don't Support Continuing Development Program to Evaluate Combinations of Mirtazapine
Go back to Cypress Bioscience (CYPB) Says Phase IIa Trials Don't Support Continuing Development Program to Evaluate Combinations of Mirtazapine| CYPRESS BIOSCIENCE (NASDAQ: CYPB) | Delayed: 6.50 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.50 | 52 Week High | $6.55 | |||
| Open | $6.35 | 52 Week Low | $2.06 | |||
| Day High | $6.50 | P/E | N/A | |||
| Day Low | $6.50 | EPS | $-1.34 | |||
| Volume | 135,162 | |||||
